blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2209485

EP2209485 - EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.02.2017
Database last updated on 02.11.2024
Most recent event   Tooltip21.09.2018Lapse of the patent in a contracting state
New state(s): MT		published on 24.10.2018  [2018/43]
Applicant(s)For all designated states
OKLAHOMA MEDICAL RESEARCH FOUNDATION
755 Research Parkway, Suite 410
Oklahoma City OK 73104 / US
[2010/30]
Inventor(s)01 / ESMON, Charles, T.
755 Research Parkway
Suite 410
Oklahoma City, OK 73104 / US
02 / XU, Jun
755 Research Parkway
Suite 410
Oklahoma City, OK 73104 / US
03 / ZHANG, Xiaomei
755 Research Parkway
Suite 410
Oklahoma City, OK 73104 / US
 [2016/13]
Former [2010/30]01 / ESMON, Charles, T.
755 Research Parkway Suite 410
Oklahoma City, OK 73104 / US
02 / XU, Jun
755 Research Parkway Suite 410
Oklahoma City, OK 73104 / US
03 / ZHANG, Xiaomei
755 Research Parkway Suite 410
Oklahoma City, OK 73104 / US
Representative(s)Dehmel, Albrecht
Dehmel & Bettenhausen
Patentanwälte PartmbB
Herzogspitalstraße 11
80331 München / DE
[2016/13]
Former [2010/30]Dehmel, Albrecht
Dehmel & Bettenhausen Patentanwälte Herzogspitalstrasse 11
80331 München / DE
Application number, filing date08847874.806.11.2008
[2010/30]
WO2008US82632
Priority number, dateUS20070985886P06.11.2007         Original published format: US 985886 P
[2010/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009061918
Date:14.05.2009
Language:EN
[2009/20]
Type: A1 Application with search report 
No.:EP2209485
Date:28.07.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 14.05.2009 takes the place of the publication of the European patent application.
[2010/30]
Type: B1 Patent specification 
No.:EP2209485
Date:30.03.2016
Language:EN
[2016/13]
Search report(s)International search report - published on:EP14.05.2009
ClassificationIPC:A61K38/17, A61K39/395, G01N33/53
[2010/30]
CPC:
A61K38/10 (EP,US); A61K31/727 (EP,US); A61K38/1709 (EP,US);
A61K38/36 (EP,US); A61K38/4833 (EP,US); A61K38/4846 (EP,US);
A61K38/4866 (EP,US); A61K39/3955 (US); A61K45/06 (EP,US);
A61P1/18 (EP); A61P11/00 (EP); A61P17/02 (EP);
A61P31/04 (EP); A61P31/10 (EP); A61P37/02 (EP);
A61P43/00 (EP); A61P9/00 (EP); A61P9/10 (EP);
C07K16/18 (EP,US); C07K16/40 (EP,US); C07K7/08 (US);
C12Y304/21005 (EP,US); C12Y304/21006 (EP,US); G01N33/6875 (EP,US);
A61K2039/505 (EP,US); C07K2317/76 (EP,US); C12Y304/21069 (EP,US) (-)
C-Set:
A61K31/727, A61K2300/00 (EP,US);
A61K38/1709, A61K2300/00 (US,EP);
A61K38/36, A61K2300/00 (EP,US);
A61K38/4833, A61K2300/00 (US,EP);
A61K38/4846, A61K2300/00 (US,EP);
A61K38/4866, A61K2300/00 (EP,US)
(-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/13]
Former [2010/30]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:EXTRAZELLULÄRE HISTONE ALS BIOMARKER ZUR PROGNOSE UND ZIELMOLEKÜLE ZUR BEHANDLUNG[2010/30]
English:EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY[2010/30]
French:HISTONES EXTRACELLULAIRES EN TANT QUE BIOMARQUEURS POUR UN PRONOSTIC ET CIBLES MOLÉCULAIRES POUR UNE THÉRAPIE[2010/30]
Entry into regional phase25.05.2010National basic fee paid 
25.05.2010Designation fee(s) paid 
25.05.2010Examination fee paid 
Examination procedure25.05.2010Examination requested  [2010/30]
28.07.2010Amendment by applicant (claims and/or description)
17.11.2010Despatch of a communication from the examining division (Time limit: M04)
15.03.2011Reply to a communication from the examining division
12.11.2012Despatch of a communication from the examining division (Time limit: M04)
22.03.2013Reply to a communication from the examining division
12.06.2014Despatch of a communication from the examining division (Time limit: M04)
29.09.2014Reply to a communication from the examining division
08.05.2015Despatch of a communication from the examining division (Time limit: M04)
13.07.2015Reply to a communication from the examining division
24.11.2015Communication of intention to grant the patent
08.02.2016Fee for grant paid
08.02.2016Fee for publishing/printing paid
08.02.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.11.2010
Opposition(s)03.01.2017No opposition filed within time limit [2017/10]
Fees paidRenewal fee
31.08.2010Renewal fee patent year 03
14.11.2011Renewal fee patent year 04
13.11.2012Renewal fee patent year 05
18.11.2013Renewal fee patent year 06
10.11.2014Renewal fee patent year 07
10.11.2015Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.11.2008
AT30.03.2016
BE30.03.2016
BG30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
IT30.03.2016
LT30.03.2016
LV30.03.2016
MC30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
TR30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
MT06.11.2016
LU30.11.2016
[2018/43]
Former [2018/38]HU06.11.2008
AT30.03.2016
BE30.03.2016
BG30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
IT30.03.2016
LT30.03.2016
LV30.03.2016
MC30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
TR30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
LU30.11.2016
Former [2018/29]HU06.11.2008
AT30.03.2016
BE30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
IT30.03.2016
LT30.03.2016
LV30.03.2016
MC30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
TR30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
LU30.11.2016
Former [2018/28]HU06.11.2008
AT30.03.2016
BE30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
IT30.03.2016
LT30.03.2016
LV30.03.2016
MC30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
LU30.11.2016
Former [2017/48]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
IT30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
LU30.11.2016
Former [2017/37]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
IT30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/07]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
IT30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/03]AT30.03.2016
BE30.03.2016
CZ30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
IT30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2016/51]AT30.03.2016
CZ30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2016/50]AT30.03.2016
CZ30.03.2016
EE30.03.2016
ES30.03.2016
FI30.03.2016
HR30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
Former [2016/49]EE30.03.2016
FI30.03.2016
HR30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
SE30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
Former [2016/48]FI30.03.2016
HR30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
SE30.03.2016
NO30.06.2016
GR01.07.2016
IS30.07.2016
Former [2016/44]FI30.03.2016
HR30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
SE30.03.2016
NO30.06.2016
GR01.07.2016
Former [2016/39]FI30.03.2016
HR30.03.2016
LT30.03.2016
LV30.03.2016
SE30.03.2016
NO30.06.2016
GR01.07.2016
Former [2016/36]FI30.03.2016
HR30.03.2016
LT30.03.2016
NO30.06.2016
GR01.07.2016
Former [2016/35]FI30.03.2016
HR30.03.2016
NO30.06.2016
GR01.07.2016
Cited inInternational search[X]EP1544214  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [X] 1,5,8-10,15,16,26-28,32,35,40-43,50 * the whole document *;
 [DX]  - ABAKUSHIN D N ET AL, "Histones evoke thymocyte death in vitro; histone-binding immunoglobulins decrease their cytotoxicity", BIOCHEMISTRY (MOSCOW), (199906), vol. 64, no. 6, ISSN 0006-2979, pages 693 - 698, XP009111475 [DX] 1,5,11-13,16-20,23,24,41-43,47,50-53 * the whole document *
 [A]  - VANI ET AL, "Histone H1 inhibits the proliferation of MCF 7 and MDA MB 231 human breast cancer cells", CELL BIOLOGY INTERNATIONAL, ACADEMIC PRESS, GB, (20060401), vol. 30, no. 4, ISSN 1065-6995, pages 326 - 331, XP005359119 [A] * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cellbi.2005.12.004
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.